Trial · NCT06873100
Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis
NCT06873100, Phase 1, Phase 2, Recruiting, Peking University People's Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis. Trials, record NCT06873100. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06873100
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis
- NCT number
- NCT06873100
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Peking University People's Hospital
- Conditions
- Relapsing Polychondritis
- Interventions
- Upadacitinib, corticosteroids and immunosuppressants
- First posted
- 2025-03-12
- Last updated
- 2025-03-12
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | CRP variation | 24 weeks | Modification of inflammatory makers |
| Secondary | Relapsing Polychondritis Disease Activity Index | 24 weeks | |
| Secondary | Variation of lymphocyte subpopulations and cytokine during the treatment of upadacitinib | 24 weeks | Cytokine and lymphocyte subgroups of T cell, B cell and NK cell are analyzed during the treatment. |
| Secondary | Improvement of clinical symptom measured by 5-level EQ-5D version (EQ-5D-5L) | 24 weeks | The EQ-5D-5L is a health-related quality-of-life instrument developed by the EuroQol Group. It is designed to measure health status across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. |
| Secondary | Alteration of inflammatory biomarkers and pathways after treatment of upadacitinib | 24 weeks | We will investigate the potential pathways through which Upadacitinib exerts its effects and examine the changes in inflammatory biomarkers during the experimental process |
| Secondary | Incidence of Treatment-Emergent Adverse Events | 24 weeks | Adverse events includes influenza-like symptoms, infection, fever, tumor,drug-induced liver and kidney damage. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06873100
GET https://conductscience.org/api/trials/v1/NCT06873100/registered